Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 100

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 100
---
, we recorded deemed dividends of $31,614,000, in connection with the triggering of a down round provision in connection
with our Series D Preferred Stock, we recorded a deemed dividend of $6,650,000, and in connection with the adjustment in the exercise
price of Series C Common Warrants, we recorded deemed dividends of $84,000. Accordingly, for the nine months ended September 30, 2025
and 2024, net loss attributable to common stockholders amounted to $47,078,000, or $(72.94) per common share, and $8,976,000, or approximately
$(587.00) per common share, respectively.

Liquidity and Capital Resources

Capital Requirements

Predecessor and the Company
have not generated any revenue from any source and the Company does not expect to generate revenue for at least the next few years. If
the Company fails to complete the timely development of, or fails to obtain regulatory approval for, its product candidates, the ability
of the Company to generate future revenue will be adversely affected. The Company does not know when, or if, it will generate any revenue
from its product candidates, and does not expect to generate revenue unless and until the Company obtains regulatory approval and commercialization
of its product candidates.

The Company expects its
expenses to increase significantly in connection with its ongoing activities, particularly as it continues and expands research, preclinical
development, and clinical development to support marketing approval for its product candidates. In addition, if the Company obtains approval
for any of its product candidates, the Company expects to incur significant commercialization expenses related to sales, marketing, manufacturing
and distribution. Furthermore, the Company expects to incur additional costs associated with operating as a public company.

The Company, therefore, anticipates
that substantial additional funding will be needed in connection with its continuing operations. As of September 30, 2025, the Company
had approximately $1.9 million in cash and cash equivalents. The Company intends to devote most of the available cash to the preclinical
and clinical development of its product candidates and public company compliance costs. Based on current business plans, the Company believes
that the cash available as of September 30, 2025 will not fund its operations and capital requirements for 12 months after the filing
of these unaudited condensed financial statements for the period ended September 30, 2025. The Company has arranged two equity lines of
credit, one providing for the